AstraZeneca adds live chat option to Nexium, Crestor sites

Share this article:
Visitors to Crestor.com and PurplePill.com can now hit a “click to chat” button to chat with a live AstraZeneca customer service rep.

The feature, which can be accessed through the sites' "Contact us” pages, will be operated by the same nurses, pharmacists and customer service reps that handle customer calls, and as with calls, will be available weekdays from 8 am-6 pm. Those clicking during off-hours will get a popup box advising them that no reps are available and that they can try back during regular business hours.

“AstraZeneca understands that our consumers want flexibility, especially when it comes to health information,” said senior director, AstraZeneca Information Center Donna Holder. “This new resource enables consumers to have easier access to the information they seek through the convenience of a real-time online channel.”

The company is one of the first in the sector to use click-to-chat, said Don Keane, VP marketing and product strategy for Angel, which offers chat and Interactive Voice Response programs. AstraZeneca launched a “Call Me Now” feature on the sites in October, giving visitors the option to skip telephone prompts, recordings and waiting on hold and instead receive an immediate phone call from a live rep.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...